Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) in a research report issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

A number of other research analysts have also issued reports on the company. EF Hutton Acquisition Co. I reiterated a “buy” rating and set a $10.00 target price on shares of Adaptimmune Therapeutics in a research report on Monday, April 17th. Bryan, Garnier & Co initiated coverage on Adaptimmune Therapeutics in a report on Friday, March 24th. They issued a “buy” rating and a $3.60 price objective on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Adaptimmune Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $6.12.

Adaptimmune Therapeutics Trading Up 2.3 %

Shares of NASDAQ:ADAP opened at $1.34 on Thursday. Adaptimmune Therapeutics has a twelve month low of $1.01 and a twelve month high of $2.65. The company’s 50 day moving average is $1.24 and its 200 day moving average is $1.58. The company has a market cap of $207.24 million, a PE ratio of -1.94 and a beta of 2.26.

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last released its quarterly earnings data on Monday, March 6th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.07. Adaptimmune Therapeutics had a negative return on equity of 101.58% and a negative net margin of 160.39%. The business had revenue of $11.03 million for the quarter, compared to analyst estimates of $7.50 million. Equities research analysts predict that Adaptimmune Therapeutics will post -0.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several institutional investors have recently bought and sold shares of the company. State Street Corp grew its position in Adaptimmune Therapeutics by 5.9% in the 1st quarter. State Street Corp now owns 284,741 shares of the biotechnology company’s stock valued at $310,000 after acquiring an additional 15,943 shares in the last quarter. UBS Group AG boosted its stake in shares of Adaptimmune Therapeutics by 1,090.8% in the 4th quarter. UBS Group AG now owns 23,625 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 21,641 shares during the period. Morgan Stanley boosted its stake in shares of Adaptimmune Therapeutics by 1.0% in the 4th quarter. Morgan Stanley now owns 2,289,848 shares of the biotechnology company’s stock valued at $3,343,000 after buying an additional 22,082 shares during the period. Two Sigma Investments LP purchased a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at about $33,000. Finally, Virtu Financial LLC boosted its stake in shares of Adaptimmune Therapeutics by 133.7% in the 3rd quarter. Virtu Financial LLC now owns 40,503 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 23,175 shares during the period.

Adaptimmune Therapeutics Company Profile

(Get Rating)

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Adaptimmune Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Adaptimmune Therapeutics wasn’t on the list.

While Adaptimmune Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here